Trial intelligence / Profile preview

PATRICIA-3

2026-526704-67-00Phase 2Authorised

Sponsor: SOLTI
Start: Oct 2026
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Countries: 1

Overview

Phase 2, open-label, single-arm trial of zongertinib, ribociclib and trastuzumab in breast cancer, sponsored by SOLTI. Primary endpoints: Incidence of dose-limiting toxicities and 6-month progression-free survival rate. Planned start Oct 2026; status: authorised.

Drugs

zongertinibribociclibtrastuzumab

Conditions

breast cancer

Beyond the preview

Go deeper on 2026-526704-67-00.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2026-526704-67-00.